You are here: Industry Insights > HBM4003

News List

Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003 prnasia
January 05, 2022
Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient...
HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021 prnasia
July 27, 2021
Harbour BioMed announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumors will be presented as an e-poster at the 2021 European Society for ...
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC prnasia
June 17, 2021
Harbour BioMed today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study.
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody prnasia
May 12, 2021
Harbour BioMed announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma (HCC) ...
Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China prnasia
March 22, 2021
Harbour BioMed (HBM) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2).
Harbour BioMed gets FDA nod to begin clinical trial for HBM4003 in cancer pharmaceutical-business-review
March 06, 2020
Harbour BioMed has secured approval from the US Food and Drug Administration (FDA) to move ahead with clinical studies in the US for its anti-CTLA-4 antibody HBM4003 for the treatment of cancer.
Harbour BioMed, PPD to Develop Oncology and Immunology Therapeutics contractpharma
August 28, 2019
Will focus on developing HBM4003, an anti-cancer immunotherapy to target solid tumors.